COR Stock - Cencora, Inc.
Unlock GoAI Insights for COR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $321.33B | $293.96B | $262.17B | $238.59B | $213.99B |
| Gross Profit | $11.48B | $9.79B | $8.96B | $8.30B | $6.94B |
| Gross Margin | 3.6% | 3.3% | 3.4% | 3.5% | 3.2% |
| Operating Income | $2.63B | $2.18B | $2.34B | $2.37B | $2.35B |
| Net Income | $1.55B | $1.51B | $1.75B | $1.70B | $1.54B |
| Net Margin | 0.5% | 0.5% | 0.7% | 0.7% | 0.7% |
| EPS | $8.02 | $7.60 | $8.62 | $8.15 | $7.48 |
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Overweight | $400 |
| June 3rd 2025 | Wells Fargo | Upgrade | Overweight | $337 |
| December 4th 2024 | Mizuho | Resumed | Outperform | $280 |
| September 18th 2024 | BofA Securities | Downgrade | Neutral | $245← $275 |
| February 26th 2024 | Leerink Partners | Initiation | Outperform | $261 |
| January 3rd 2024 | Barclays | Initiation | Overweight | $242 |
| December 14th 2023 | Wells Fargo | Initiation | Equal Weight | $213 |
Earnings History & Surprises
COREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | $4.04 | — | — | — |
Q4 2025 | Nov 5, 2025 | $3.79 | $3.84 | +1.3% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $3.85 | $4.00 | +3.9% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $4.11 | $4.42 | +7.5% | ✓ BEAT |
Q1 2025 | Feb 5, 2025 | $3.50 | $3.73 | +6.6% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $3.23 | $3.34 | +3.4% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | — | — | — | — |
Q2 2024 | Apr 30, 2024 | — | — | — | — |
Q1 2024 | Jan 30, 2024 | — | $2.98 | — | — |
Q4 2023 | Nov 2, 2023 | $2.79 | $1.72 | -38.4% | ✗ MISS |
Q3 2023 | Aug 2, 2023 | $2.82 | $2.92 | +3.5% | ✓ BEAT |
Q2 2023 | May 2, 2023 | $3.29 | $3.50 | +6.4% | ✓ BEAT |
Q1 2023 | Feb 1, 2023 | $2.64 | $2.71 | +2.7% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $2.58 | $2.60 | +0.8% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $2.57 | $2.62 | +1.9% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $2.93 | $3.22 | +9.9% | ✓ BEAT |
Q1 2022 | Feb 2, 2022 | $2.58 | $2.58 | 0.0% | = MET |
Q4 2021 | Nov 4, 2021 | $2.36 | $2.39 | +1.3% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $2.01 | $2.16 | +7.5% | ✓ BEAT |
Latest News
Cencora Boosts Long-Term Adj. EPS Outlook To 10%-14% On Expected Contribution From Acquisition Of OneOncology
📈 PositiveCencora Reiterates FY26 Guidance; Pauses Buybacks Ahead Of OneOncology Deal, FY26 Adj. EPS Seen At Lower Half Of Its $17.45-$17.75 Guidance Range
➖ NeutralCencora To Acquire Majority Stake In OneOncology From TPG And Other Shareholders For ~$3.6B, Retire $1.3B Debt In $5B Cash Deal
📈 PositiveBarclays Initiates Coverage On Cencora with Overweight Rating, Announces Price Target of $400
📈 PositiveJP Morgan Maintains Overweight on Cencora, Raises Price Target to $417
📈 PositiveWells Fargo Maintains Overweight on Cencora, Raises Price Target to $405
📈 PositiveTD Cowen Maintains Buy on Cencora, Raises Price Target to $400
📈 PositiveUBS Maintains Buy on Cencora, Raises Price Target to $415
📈 PositiveBaird Maintains Outperform on Cencora, Raises Price Target to $395
📈 PositiveMizuho Maintains Outperform on Cencora, Raises Price Target to $380
📈 PositiveCencora Board Approves 9% Increase In Quarterly Dividend To $0.60 Per Share, Payable December 1, 2025
📈 PositiveCencora Sees FY2026 Adj EPS $17.45-$17.75 vs $15.94 Est; Sees Sales $337.365B-$343.791B vs $321.030B Est
📈 PositiveCencora Q4 Adj. EPS $3.84 Beats $3.79 Estimate, Sales $83.700B Beat $83.458B Estimate
📈 PositiveMizuho Maintains Outperform on Cencora, Raises Price Target to $340
📈 PositiveUBS Maintains Buy on Cencora, Raises Price Target to $380
📈 PositiveMizuho Maintains Outperform on Cencora, Raises Price Target to $334
📈 PositiveCencora's IntrinsiQ Expands Oncology Biomarker Data And Therapeutic Insights To Advance Precision Medicine And Support Biopharmaceutical Innovation
📈 PositiveMcKesson boosts Cencora, Cardinal after guidance hike
📈 PositiveU.S. Health Secretary Kennedy On Pharmacy Benefit Managers, Says In Talks With Industry, Pharma Cos; Have Committed To Some Protocol For Transparency; MFN Talks Would Include Direct-To-Consumer Marketing; Cannot Give Timing On Mifepristone Review
➖ NeutralCencora Appoints Mark Durcan As Chairman Of The Board, Effective October 1, 2025, Succeeding Steven Collis
➖ NeutralFrequently Asked Questions about COR
What is COR's current stock price?
What is the analyst price target for COR?
What sector is Cencora, Inc. in?
What is COR's market cap?
Does COR pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to COR for comparison